SGLT2 inhibitors, what the emergency physician needs to know: a narrative review

Article Article scientifique Revue de la littérature SGLT2 inhibitors, what the emergency physician needs to know: a narrative review eng 2021-05-10 2021-05-10 author Lu Henri 0000-0002-9074-6505 author Lu Hortense author Kosinski Christophe 0000-0002-7544-498X author Wojtusciszyn Anne author Zanchi Anne author Carron Pierre-Nicolas author Müller Martin 0000-0003-4067-7174 author Meyer Philippe author Martin Jehan 596344 author Muller Olivier author Hullin Roger 2036 10.3390/jcm10092036 34068655 2077-0383 PMC8126052 Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin belong to a class of antidiabetic treatments referred to as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors, or SGLT2is). SGLT2is are currently indicated in North America and in Europe in type 2 diabetes mellitus, especially in patients with cardiovascular (CV) disease, high CV risk, heart failure, or renal disease. In Europe, dapagliflozin is also approved as an adjunct to insulin in patients with type 1 diabetes mellitus. New data provide evidence for benefits in heart failure with reduced ejection fraction and chronic kidney disease, including in patients without diabetes. The use of SGLT2is is expected to increase, suggesting that a growing number of patients will present to the emergency departments with these drugs. Most common adverse events are easily treatable, including mild genitourinary infections and conditions related to volume depletion. However, attention must be paid to some potentially serious adverse events, such as hypoglycemia (when combined with insulin or insulin secretagogues), lower limb ischemia, and diabetic ketoacidosis. We provide an up-to-date practical guide highlighting important elements on the adverse effects of SGLT2is and their handling in some frequently encountered clinical situations such as acute heart failure and decompensated diabetes. Diabetes Guidelines Heart failure Renal Dewey 616 Dewey 617 56 Département de médecine 221 63 Département d'anesthésiologie, pharmacologie, soins intensifs et urgences 229 false Journal of clinical medicine 10 9 70851753-04e2-40c5-895b-bc4c3d8bcd6f Article (Published version) Public Article-scientifique-from-europePmc.pdf 257901 application/pdf CC BY openAccess Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences

Title	Published in	Access level	OA Policy	Year	Views	Downloads

SGLT2 inhibitors, what the emergency physician needs to know: a narrative review	Journal of clinical medicine			2021	178	365

Archive ouverte UNIGE

Martin, Jehan